STXBP1

Across TCGA pan-cancer cohorts, STXBP1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STXBP1 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher STXBP1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated STXBP1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where STXBP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.745	0.468	.006	15	view →
LSCC	DFS	Tertile	II,III,IV	0.824	1.000	.022	6	view →
PDAC	OS	Median	III,IV	1.000	0.537	.008	5	view →
CCRCC	DFS	Median	III,IV	0.818	0.244	.031	4	view →
GBM	OS	Tertile	All	0.921	0.822	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STXBP1–LUAD (DFS)

Open the LUAD breakdown →